Saturday 17 October 2026
Export LNSR’s income statement to Excel — free account
LENSAR, Inc.
LNSR Healthcare Medical Devices
LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024. In the quarter to June 2026, revenue grew 18.4%, EPS grew 291.7% and free cash flow grew 96.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
5.80
0.23
−3.81%
Follow LNSR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 2.48 | 2.01 |
P/S ratio |
2.52 | 2.38 | 1.26 | 1.17 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(42.34) | 225.03 | (16.97) | (552.88) | |
P/B ratio |
0.00 | 0.00 | 6.72 | 4.71 | |
Price to Tangible BV |
0.00 | 0.00 | 12.44 | 6.90 | |
EV/Sales |
2.34 | 2.18 | 1.13 | 1.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.72) | (8.59) | (5.37) | (8.63) | |
EV/FCF |
(11.63) | (8.54) | (5.33) | (8.50) | |
Quick Ratio |
0.64 | 0.60 | 1.03 | 1.00 | |
Current Ratio |
1.24 | 1.15 | 2.38 | 2.39 | |
Net Debt/EBITDA |
2.60 | 4.78 | (4.00) | (4.19) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.89 | 0.85 | 0.83 | 0.86 | |
Operating CF/Net income |
0.95 | (0.42) | (0.12) | (0.04) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.03) | |
Research and Development Expense of Revenue |
9.55% | 8.09% | 10.31% | 7.72% | |
Selling, General and Administrative Expense of Revenue |
83.96% | 64.46% | 18.83% | 37.23% | |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
5.94% | 5.45% | 5.14% | 2.10% | |
Graham Net Nets |
(0.35) | (0.36) | (0.18) | (0.11) | |
Graham Number |
14.58 | 11.92 | 6.93 | 8.81 | |
Earnings Yield |
(35.55%) | (24.94%) | 40.40% | 49.83% | |
Free Cash Flow Yield |
(7.99%) | (10.72%) | (16.90%) | (10.55%) | |
Revenue per Share |
1.19 | 1.34 | 1.10 | 1.34 | |
Operating CF per Share |
(0.29) | 0.05 | (0.35) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.29) | 0.05 | (0.35) | (0.01) | |
Cash per Share |
1.40 | 1.50 | 1.11 | 1.10 | |
Shareholders Equity per Share |
(2.15) | (2.18) | 0.89 | 1.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.15) | (2.18) | 0.89 | 1.21 | |
Free Cash Flow |
(3.51) | 0.62 | (4.27) | (0.16) | |
Working Capital |
8.70 | 6.20 | 24.60 | 27.39 | |
Capital Expenditures |
0.00 | 0.00 | — | (0.03) | |
Net Current Asset Value |
(51.68) | (50.68) | (13.03) | (7.63) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.14 | 6.23 | 5.89 | 5.58 | |
Average Payables |
9.33 | 12.49 | 8.93 | 11.25 | |
Average Inventory |
17.74 | 16.47 | 19.21 | 22.06 | |
Average Assets |
66.11 | 68.86 | 69.59 | 69.99 | |
Average Common Equity |
(1.58) | (10.58) | (5.68) | (4.07) |
Columns are period end dates